On Friday, the US Food and Drug Administration removed semaglutide injection products from its ... In its earnings report, Hims credited these weight-loss drugs for growth in online revenue ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug ... offering these products in the same ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update ... Drug Administration removed semaglutide injection products from its shortage list and gave compounders ...